List of APIs/Active Pharmaceutical Ingredients Companies in India - 27

Beta Drugs Ltd. is a dedicated world leader in oncology. BDL is a Global leader in the development of enabling products, scientific knowledge, and technical expertise within a wide range of applications. At Beta DrugsLtd. (BDL.) we are improving both the speed to market of our products and the value of our product introductions to customers. Inspired by a newly-formed breakthrough innovation group, Beta Drugs Ltd. (BDL.) is actively exploring opportunities that stretch business and technology boundaries.

Established in 2002 into API manufacturing, we have a consolidated position in the domestic and global market for the API Business. In today's dynamic global pharmaceutical market, we at BDR Pharmaceuticals have carved a niche for ourselves, with our formulations portfolio for specialty medication. Our unique strategy of multi-branding ensures that critical and lifesaving medicines are available at affordable prices with two API and formulation facilities at Gujarat, Uttarakhand and a pellet facility at Hyderabad.

Biophore is a research driven global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs) having its operations based in Hyderabad, India and also has a registered office in New Jersey, USA. Biophore has two dedicated R&D facilities in Hyderabad and Vishakapatnam. The research facilities are fully equipped with wide range of R&D and process equipment from USA with reaction capabilities from milligram to kilogram. Ever since its establishment in 2007, Biophore recognized that there were two ways of growing the API business: manufacture a large API product basket, or pick a handful of promising APIs in select therapeutic categories and grow them over the long-term. Biophore consciously chose the latter option and focused on not only building competencies and adding scale in those segments but more importantly, building efficiencies that would make it an undisputed leader in these products of choice. The product range is constantly expanded through its own R&D, process development, technology transfers, joint ventures and collaborations. Biophore's core strength lies in development of non – infringing routes for comprehensive range of bulk actives and intermediates, development of niche APIs, oncology APIs, APIs for MRI contrast agents and APIs for NCE - 1 filing. Biophore has made strategic investments in two manufacturing facilities. Sionc pharmaceuticals & Azico – Biophore, Both located at Vishakapatnam. Among them Sionc, a multi-purpose plant has passed FDA inspection in 2013 & 2016 with no observations on the Form 483. This is the reason to be proud and confirmation of the highest quality standards of Biophore. Our other facility Azico – Biophore is also a n FDA approved facility that strictly complies with cGMP procedures and maintains well documented SOPs, with a modern quality control laboratory thereby ensuring the production of highest quality APIs.

Founded by Shri I.A. Modi, Cadila Pharmaceuticals Ltd. is one of the largest privately held pharmaceutical companies in India, headquartered at Ahmedabad, in the State of Gujarat. Over the last seven decades, the company has been developing and manufacturing pharmaceutical products in India and selling and distributing these in over hundred other countries around the world. Focused strongly on Innovation and Research, the company is present in more than forty-five therapeutic areas spread across twelve specialities, including cardiovascular, gastrointestinal, analgesics, haematinics, anti-infectives and antibiotics, respiratory agents, antidiabetics and immunologicals. At Cadila Pharmaceuticals, Research and Development is at the core of all its initiatives, be it Biotechnology, APIs, Formulations, Plant Tissue Culture or Phytochemistry. More than 300 scientists in its various Research and Development setups reinforce the competitiveness of research in the therapeutic areas which have high unmet medical needs. Cadila Pharmaceuticals Excellence in manufacturing facilities is central to Cadila Pharmaceuticals. The company’s formulations manufacturing plant at Dholka near Ahmedabad, Gujarat is spread over hundred acres of land. This state-of-the- art facility is not only impressive in size, but is also USFDA approved. The second formulations manufacturing facility is located at Samba in Jammu and Kashmir. The facility meets most of the stringent quality standards across the globe to produce tablets, capsules, soft and hard gelatin capsules, liquids and orals. Two Active Pharmaceutical Ingredient (API) manufacturing units at Ankleshwar, Gujarat manufacture a wide range of APIs and intermediates including many USFDA-certified products. The company has strong foothold in the African continent through its formulation manufacturing facility at Addis Ababa in Ethiopia. For more information visit: https://www.cadilapharma.com/

Calyx Chemicals & Pharmaceuticals Ltd. is a manufacturer of Active Pharmaceutical Ingredients (APIs) and intermediates, based in India. With over 40 years of experience, the company operates a US FDA-inspected facility in Tarapur, Maharashtra. It specializes in APIs for anti-TB and anti-malarial therapeutic areas and offers custom synthesis of pharmaceutical intermediates. Calyx provides integrated services through its Contract Research and Manufacturing Services (CRAMS), which encompass API development and contract manufacturing. The company has a strong regulatory compliance record, having successfully passed audits from USFDA, EDQM, and WHO. It serves a global customer base, focusing on regulated markets such as the US and Europe.

Centaur Pharmaceuticals ranks among India’s few, fully integrated pharmaceutical firms with proficiencies across the pharmaceutical value chain. Centaur leverages its synergies across API, R&D, CRAM, Clinical Research and formulations to provide end-to-end solutions to prestigious pharmaceutical partners.

Century Pharmaceuticals Ltd is a privately held Pharmaceutical Company based out Vadodara, India. For more than 30 years, we have emerged as a respectable name in the industry. Our services include manufacturing APIs, facilities for contract manufacturing, Biotechnology research, API research, stability studies, and more.

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Concord Biotech Limited is an R&D based Biotechnology company, having focus on the fermentation, semi-synthetic and synthesis based products. Since its inception in 2000, Concord has recorded an excellent growth through diversification and process improvements. Having state-of-the-art US FDA & EUGMP approved facility; Concord is a professionally managed globally recognised supplier of fermentation based API’s and enzyme & offers services in biotechnology area like strain improvement & contract fermentation/ manufacturing. The existing portfolio of products includes API’s in the immunosuppressant, antibiotic, Oncology , Anti-Obesity, hypolipemic segments and enzymes. However, with the expertise in the field of biotechnology and chemistry, the R&D team at Concord is working towards adding new products to the product basket.

Dishman is a global, dynamic group of companies offering a continuum of services to the pharmaceutical industry. We are a global outsourcing partner for pharmaceutical companies, offering a portfolio of products and development, scale-up and manufacturing services. The Dishman Group continually invests in the pharmaceutical industry, ensuring Dishman’s businesses can provide pharmaceutical customers with high-value, high-quality products and services today and in the future. Our focus is to add value to the global pharmaceutical industry by serving as a reliable partner. Our business is successful only when our customers are successful.

A Public limited firm in the business of manufacturing and supply of High quality Generic Active Pharmaceutical Ingredients (APIs) to the Global Pharmaceutical Industry since 1995.

Established in Hyderabad, India in 1978, Gland Pharma is one of the fastest-growing small-molecule generic injectables-focused company, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets in the rest of the world. Gland Pharma has seven manufacturing facilities in India, comprising four facilities for finished formulations and three API facilities. We are focused on meeting diverse injectables needs with a stable supply of affordable and high-quality products. We have established a portfolio of injectables products across various therapeutic segments and delivery systems and are present in sterile injectables, oncology and ophthalmics with a focus on complex injectables.

Ions Pharma is is involved in Manufacturing and trading of pharmaceutical API's ,veterinary API's, Food chemicals, Food additive, Excipients.

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

Metrochem API is one of the fastest growing manufacturers of Active Pharmaceutical Ingredients (APIs), Pellets (Semi finished Formulations) and Intermediates in Multi Therapeutic segments like Antiulceratives, Antifungals, Antidepressants, Antihypertensives, AntiThrombotic, Antihistaminic, Antilipemic, Antiarthritic, Antiinflammatory, Antidiabetic, Antibacterial, Gastoprokinetic. We have total Six State- of- the-Art production facilities based in Hyderabad & Vishakapatnam, India. To cater our customer high volume requirements, we have dedicated each of our 6 manufacturing facilities to our 3 core product groups – APIs, Pelletization& Intermediates – reinforeced by a well equipped, centralized Research & Development laboratory. Our facilities are ISO 9001-2008, WHO: GMP, USFDA, Cofepris and Japanese Accredited approved. Inspected by KFDA authorities and awaiting for certification andmoving towards EUGMP, MHRA &TGA in 2015. Metrochem API management team having of top notch professionals, with extensive experience in Organic chemistry. Our most valuable resource is its people, It is a Knowledge driven company with dedicated professionals at the helm handling operations in Research & Development, Production, Quality Assurance, Marketing, Supply Chain and Finance.

Morepen Laboratories Limited is an Indian pharmaceutical company founded in 1984. It focuses on providing affordable and high-quality healthcare solutions through innovative pharmaceutical and medical technology products. The company is committed to excellence and aims to make health accessible worldwide. Morepen offers a diverse range of products, including high-quality Active Pharmaceutical Ingredients (APIs) such as Loratadine and Atorvastatin, as well as formulation products across various therapeutic categories like antibiotics and analgesics. The company also has a strong presence in the medical devices sector, particularly with its Blood Glucose and Blood Pressure Monitors. Morepen operates three manufacturing plants in Himachal Pradesh, India, and has a well-equipped R&D center that emphasizes innovation. With a robust distribution network of over 5,100 distributors and 328,000 retail touchpoints in India, Morepen exports its products to more than 50 countries, establishing itself as a significant player in the global generic drug market.

MSN Group is one of the fastest-growing, research-based and fully integrated pharmaceutical companies based out of Hyderabad, India. It was founded in the year 2003 with a mission to make high-quality medicines affordable and accessible to the world. The organization presently has 22 state-of-the-art manufacturing facilities (15 API and 7 Finished Dosage Facilities) established across India and USA. The group has an integrated R&D centre that facilitates the research of both API and Finished Dosages under one roof, enabling the organization to introduce new and affordable therapies in global markets swiftly. Backed by a dedicated and experienced team of over 14,000 qualified professionals, the organization has earned a global distinction for its innovation, quality and speed of delivery besides achieving the following: > About 900+ national and international patent applications filed > Product portfolio of 450 + APIs & 300+ Finished Dosages > Over 35 major therapeutic offerings covering Oncology, Cardiology, CNS, Diabetes, Nephrology, Urology, Gastroenterology, Orthopaedics etc. > World No. 1 in active US DMF Filings > Won the trust of more than 40 Million patients across 100+ countries The organizational environment at MSN Labs integrates multiple disciplines and functions by effective implementation of goals and objectives through technology coupled with Integrity, Imagination and Innovation. The company's proactive marketing, robust IP strategy, innovative R&D expertise, dynamic SCM, Insight-driven IT, and world-class facilities remain at the heart of its continuing success. We own a track record of growing at an exponential pace since our inception. From 22 Million USD in 2005 to achieving about 670 Million USD turnover in FY 2021-22 and counting, we continue to expand our growth and global footprint by creating innovative solutions for tomorrow's healthcare requirements.

NATCO Pharma is a vertically integrated company dedicated to the development, manufacture, and supply of pharmaceutical and agrochemical products. Established with the mission to make specialty medicines accessible to all, we are rooted in integrity, respect, openness, collaboration, creativity, and quality. Founded in 1981, we now have a strong global presence in over 50 countries. NATCO has emerged as an esteemed pharmaceutical company with a presence in Finished Dosage Formulations (FDF) and Active Pharmaceutical Ingredients (APIs) in both domestic and international markets. NATCO Pharma's focused approach has led to expanded capabilities across diverse therapy segments, particularly in oncology. We operate in two key segments: Pharmaceuticals and Agrochemicals. Our expertise excels in the FDF division, crafting intricate pharmaceutical solutions tailored to specific therapeutic needs. In the manufacturing of APIs, we maintain high quality and adhere to all regulatory standards with a focus on innovation. In the Crop Health Sciences (CHS) division, we produce high-value agricultural input products to meet farmers' demands, including environmentally safer biocontrol products. Operating globally, NATCO's work contributes to its diverse market presence. NATCO believes in sustainable and balanced growth through the synergy of our talented workforce and an innovative culture. We are dedicated to maximizing shareholder value creation through innovation, employee engagement, process and system optimization.

Neuland Laboratories is a leading manufacturer of active pharmaceutical ingredients (APIs) and an end-to-end chemistry-related solutions provider for the pharmaceutical industry. With three FDA-inspected facilities, 846+ DMFs, 1000+ employees and customers in more than 85 countries, Neuland supports some of the world's best-known and most successful pharmaceutical research and manufacturing companies. The spirit of research and professionalism pervades Neuland's corporate culture. Neuland's manufacturing capabilities and competence in complex chemistry provides reliable and superior quality products and services. Neuland is a leading manufacturer of APIs and provides customers with: * Contract research, contract manufacturing and generic APIs * 75 API's in 10 diverse therapeutic areas * 3 regulatory approved manufacturing facilities * 40,000 sq. ft. state-of-the-art R&D facility in Hyderabad * 300 + scientists working in R & D * Listed on the Bombay Stock Exchange and National Stock Exchange * Worldwide compliant facilities (WHO, US FDA, EMA, PMDA, TGA, KFDA, ANVISA, ISO 14001, ISO 27001 and OHSAS 18001 Certified) Neuland's core strategy is to never to compete with its customers. Neuland focuses purely on serving the global pharmaceutical firms with API manufacturing, and contract research & manufacturing services.

At PlatinumRx, we are revolutionizing the pharma industry with transparency and affordability. Empowering you with the best medicine choices at unbeatable prices. Breaking barriers in healthcare, we're not just another e-pharmacy; we're a movement towards informed, cost-effective health solutions. Join our journey!

Satya is a DDR focused drug discovery company, and has pioneered RAD51 inhibition as a potentially foundational therapeutic for high replication stress solid tumors. In addition to first- and best-in-class DDR programs, Satya additionally focuses on targeted pan-cancer therapeutics that can address a wide variety of tumors Satya's world-class scientific team is driven by a commitment to excellence, and has experience of working on over 75 targets that have led to over 15 global clinical programs, including one FDA-approved oncology drug

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is a prominent global pharmaceutical company based in India. Established in 1983, it has grown to become the largest pharmaceutical company in India and the fifth-largest specialty generic pharmaceutical company worldwide. Sun Pharma specializes in generic and specialty pharmaceuticals, focusing on chronic therapies in areas such as cardiology, psychiatry, neurology, gastroenterology, and oncology. The company operates in over 100 countries, with significant markets in the U.S., India, and emerging economies. Sun Pharma produces a diverse range of off-patent generic drugs, including tablets, capsules, injectables, and topical formulations. It also develops complex generics and specialty products for various conditions. The company has a strong commitment to research and development, investing in novel drug delivery systems and biosimilars. With 43 manufacturing facilities across five continents and a workforce of over 37,000, Sun Pharma continues to expand its global footprint and enhance its product offerings.

THINQ is a totally vertically integrated service and product provider for pharmaceutical companies offering the below services: - Contract R&D Contract Manufacturing - API Development, Manufacturing and Marketing - Formulation Development & Marketing

Turtle Pharma is a Private Pharmaceutical Company, with Headquarters in Mumbai, and Plant located near Vadodara, Gujarat, engaged in manufacturing of Active Pharmaceutical Ingredients. Turtle Pharma Private Limited Our main aim is to manufacture Active Pharmaceutical Ingredients, in conformity with regulations in force concerning the quality of pharmaceutical products, environment, safety and the health of consumers and citizens.

Wockhardt is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. It is India’s leading research-based global healthcare enterprise with relevance in the fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Specialty Hospitals. Wockhardt is a true Indian Multi-National Company with a multi-ethnic workforce of 3000 Wockhardt Associates from 21 different nationalities globally. It has 3 research centers and 12 manufacturing plants, with businesses ranging from the manufacture and marketing of Pharmaceutical and Bio-pharmaceutical formulations, Active Pharmaceutical Ingredients (APIs) and Vaccines. Headquartered in Mumbai, India, Wockhardt has full-fledged operations in the USA, UK, Ireland and France. It also has its marketing presence in emerging markets of Russia, Brazil, Mexico, Vietnam, Philippines, Nigeria, Kenya, Ghana, Tanzania, Uganda, Nepal, Myanmar, Sri Lanka, Mauritius, Lebanon and Kuwait. Wockhardt’s core business is innovation. It uses science and technology to develop medicines and other products that improve the quality of millions people’s lives through better health. Wockhardt aspires to create a healthier world. Its strategic vision of ‘More & More with Less & Less’ has transformed into new ways of thinking, a new journey for growth, medical breakthroughs for patients and continuing value for all stakeholders.